RxDoctor Payments DataLook up a doctor →

Rachel Gibbs, MD

Obstetrics & Gynecology · Tulsa, OKNPI 1255330007

Payments from drug & device makers

$11,977in general payments, 2019–2025

Across 485 payments — averaging $24.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • Acessa Health Inc.$2K
  • AbbVie$2K
  • Mayne Pharma Commercial LLC$821
  • Astellas Pharma US Inc$683
  • Hologic Sales And Service, LLC$582
  • plus $4K from 49 others

What the payments were for

  • Consulting fees$4003%
  • Travel & lodging$2,63922%
  • Food & beverage$8,41670%
  • Education$2232%
  • Gifts$3003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,977 in reported general payments places this provider in the 90th percentile of 396 obstetrics & gynecology providers in Oklahoma.

See all obstetrics & gynecology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$99,975
Medicare patients
246
Services billed
591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol459$21,321
MyrbetriqMirabegron14$15,357
PremarinEstrogens, Conjugated32$15,049
MovantikNaloxegol Oxalate13$5,175
ValacyclovirValacyclovir Hcl62$4,285
Clobetasol Propionate58$3,240
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet21$3,160
Raloxifene Hcl11$2,382
Estradiol (Twice Weekly)Estradiol22$2,115
Solifenacin Succinate13$1,869
Estradiol (Once Weekly)Estradiol11$1,675
FyavolvNorethindrone Ac/Eth Estradiol11$1,178
Fluconazole67$1,021
Alendronate Sodium58$914
Acyclovir22$869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$683$15,35714 claims
PfizerPremarin$247$15,04932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 396 obstetrics & gynecology providers in Oklahoma.

Other obstetrics & gynecology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →